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Abstract
The transcription factor Bcl6 is required for the development of the follicular helper T (TFH) cells. 
Cytokines that activate Stat3 promote Bcl6 expression and TFH cell differentiation. Previous 
studies with an acute virus infection model showed that TFH cell differentiation was decreased but 
not blocked in the absence of Stat3. In this study, we further analyzed the role of Stat3 in TFH 
cells. In Peyer’s patches (PPs), we found that compared to wild-type, Stat3-deficient TFH cells 
developed at a 25% lower rate, and expressed increased IFNγ and IL-4. While PP germinal center 
B (GCB) cells developed at normal numbers with Stat3-deficient TFH cells, IgG1 class switching 
was greatly increased. Following immunization with Sheep Red Blood Cells (SRBC), splenic 
Stat3-deficient TFH cells developed at a slower rate than in control mice and splenic GCB cells 
were markedly decreased. Stat3-deficient TFH cells developed poorly in a competitive bone 
marrow chimera environment. Under all conditions tested, Stat3-deficient TFH cells over-
expressed both IL-4 and Bcl6, a pattern specific for the TFH cell population. Finally, we found in 
vitro that repression of IL-4 expression in CD4 T cells by Bcl6 required Stat3 function. Our data 
indicate that Stat3 can repress the expression of Bcl6 and IL-4 in TFH cells, and that Stat3 
regulates the ability of Bcl6 to repress target genes. Overall, we conclude that Stat3 is required to 
fine-tune the expression of multiple key genes in TFH cells, and that the specific immune 
environment determines the function of Stat3 in TFH cells.
Introduction
In the course of an immune response, CD4 T helper cells differentiate into unique effector 
lineages that promote different immune responses via the secretion of specialized effector 
cytokines. Follicular T helper (TFH) cells are a CD4 T cell lineage whose identified function 
is to promote formation of germinal centers (GCs) and select B cell clones that produce 
high-affinity antibodies (Abs) (reviewed in (1-5)). TFH cells are typically identified as CD4+ 
CXCR5+ and PD-1high T cells, and have an activated T cell phenotype but are CD25neg. TFH 
cells control the outcome of the GC B cell response, and are critical for memory B cell and 
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plasma cell development. TFH cells produce IL-21, a cytokine that potently promotes B cell 
activation and Ab secretion. While TFH cells are required for the production of high affinity 
Abs, excessive numbers of TFH cells can promote autoimmunity by helping B cells produce 
self-reactive Abs (6-8). The proper regulation of TFH cell differentiation is therefore 
essential for strong antibody responses and preventing development of autoimmune disease.
The Bcl6 transcriptional repressor protein is up-regulated in TFH cells and is considered a 
master regulator for the TFH lineage (9-11). Signal transducer and activator of transcription 
(Stat) factors are upstream of Bcl6 in TFH cell differentiation and receive cytokine signals to 
bind to the Bcl6 promoter and induce high levels of Bcl6 expression. Specifically, activated 
CD4 T cells exposed to the cytokines IL-6, IL-21 and IL-12 activate Stat3 and Stat4 to 
promote TFH cell differentiation via up-regulation of Bcl6 (1, 2, 12-15). Stat1, activated by 
IL-6 or type I IFN can also promote Bcl6 transcription and TFH cell differentiation (16, 17), 
although in certain contexts, type I IFN can inhibit TFH cell differentiation (18).
Although Stat3 is not required for early T cell development (19, 20), Stat3 plays many 
important roles in T cell immune responses, particularly in the development of the pro-
inflammatory TH17 lineage (21-25) and formation of T cell memory (26, 27). Furthermore, 
Stat3 is required for TH17-mediated colitis, as well as regulatory control of colitis (28, 29). 
Mutations in Stat3 can lead to disease termed Hyper IgE Syndrome (HIES), which is 
characterized by elevated IgE, repeated infections, chronic dermatitis and lack of Th17 cells 
(30). HIES has a complex pathology and aspects of the disease appear to be mediated by 
non-lymphoid and even non-hematopoietic cells (31).
Two previous studies on the role of Stat3 in TFH cell differentiation following lymphocytic 
choriomeningitis virus (LCMV) infection revealed that TFH cell development was not 
strictly dependent on Stat3 function (17, 18). Thus, LCMV induced a delayed (17) or 
weakened (18) TFH cell response in CD4-cre Stat3fl/fl conditional KO mice, where Stat3 was 
deleted specifically in T cells. Ray et al (18) revealed that part of the defect in TFH cell 
development in the LCMV system was due to the failure to properly up-regulate Bcl6 in the 
absence of Stat3, a defect that was partially due to heightened sensitivity to Type I IFN 
signaling in Stat3-deficient CD4 T cells (18). Additionally, Stat3-deficient CD4 T cells 
responding to LCMV developed a strong TH1 phenotype (18), indicating that Stat3 has an 
important role in repressing TH1 cell development. However, a major question unaddressed 
by these studies was whether the findings observed for Stat3 and TFH cells in a LCMV 
infection model were broadly applicable to the role of Stat3 in TFH cell responses in other 
immune contexts. We therefore used CD4-cre Stat3fl/fl conditional knockout mice to 
examine TFH cell differentiation in the gut immune response, in Peyer’s Patches, as well as 
with immunization with a strong inducer of the germinal center response, Sheep Red Blood 
Cells (SRBC). Our data contrasts with the Ray et al study on Stat3 in TFH cells on the 
control of Bcl6 and IL-4 expression by Stat3 (18), and thus provides important new insights 
into the role of Stat3 in Bcl6 expression and TFH cell differentiation.
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Materials and Methods
Mice and immunizations
Stat3fl/fl mice (18) were backcrossed to CD4-cre transgenic mice and the C57BL/6 strain for 
at least six generations (32). TCR-transgenic OT-II mice and B6.SJL-PrprcaPepcb/BoyJ 
(BoyJ) mice were purchased from The Jackson Laboratory (JAX). Control mice for CD4-cre 
Stat3fl/fl (STAT3KO) mice were litter-mate Stat3fl/fl (WT) mice. Mice were bred under 
specific pathogen-free conditions at the laboratory animal facility at IUSM and were 
handled according to protocols approved by the IUSM Animal Use and Care Committee. 
For sheep red blood cell (SRBC) immunization, mice were intraperitoneally (i.p.) injected 
with 1 × 109 SRBCs (Rockland Immunochemicals) and were sacrificed at the indicated day. 
For Ovalbumin (OVA; Sigma) immunization, 50 ug OVA was mixed with Imject Alum 
(Pierce), and the mixture was injected i.p.
Cell culture and retrovirus transduction
CD4+CD62L+ WT and STAT3KO OT-II T cells were isolated with the CD4+CD62L+ T 
cell isolation kit II (Miltenyi), then were activated with 1ug/ml OVA peptide (Anaspec) and 
spleen-derived APCs for 3 days (one round) or 5 additional days (two rounds) under TH2 
culture conditions: 40ng/ml IL-4 (Peprotech), 10ug/ml anti-IFNg and anti-IL-12 (BioXCell). 
After 3 or 8 days of culture, cells were collected for ICS as described below. For retroviral 
transduction, CD4+CD62L+ WT and STAT3KO T cells were activated with 1ug/ml anti-
CD3, 2 ug/ml anti-CD28 and splenic APCs under Th2 condition. At 40h, cells were spin 
infected with control H2Kk, Bcl6-H2Kk-expressing retroviruses. After spin infection, 
supernatant were removed and fresh TH2 condition medium with 10 U/ml rhIL-2 were 
added back to cell culture. 3 days later, cells were collected for ICS as described below. 
Cytokine levels of H2Kk+ cells were assessed using flow cytometry.
Flow cytometry reagents
Anti-CXCR5 (2G8), anti-CD95 (Jo2), GL7 (GL7), anti-active Caspase3 (C92-605), anti-
IL-4 (11B11) and anti-Bcl6 (K112-91) Abs were from BD Biosciences. Fixable viability 
dye, AnnexinV detection kit, and anti-CD38, anti-IL-13 (eBio13A), anti-IL-21 (mhalx21), 
anti-Gata3 (TWAJ), and anti-Foxp3 (FJK-16s) Abs were from eBioscience. Anti-CD4 
(GK1.5), anti-B220 (RA3-6B2), anti-IgG1 (RMG1-1), anti-CD45.1 (A20), anti-PD-1 (29F.
1A12), anti-IL-10 (JES5-16E3), anti-interferon-γ (XMG1.2) were from Biolegend.
Cell staining for flow cytometry
After red blood cell lysis, total spleen cells were incubated with anti-mouse CD16/CD32 
(BioXcell) for 5 minutes at RT, followed by surface staining for the indicated markers. For 
intracellular transcription factor staining, after surface markers were stained, cells were fixed 
and stained with antibodies against transcription factors by following Foxp3 fixation kit 
(eBioscience) instructions. Cell events were collected on an LSR2 flow cytometer (Becton 
Dickonson).
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Intracellular cytokine staining (ICS)
Cells were stimulated with PMA (75ng/mL) plus ionomycin (1ug/mL) for 5 hours in 
DMEM cell culture medium, then fixed and stained for indicated cytokines as described 
(33). Golgistop and Golgiplug (BD Biosciences) were used during the stimulation to inhibit 
cytokine secretion.
Adoptive cell transfers and immunization
CD4+CD62L+ MACS-purified WT and STAT3KO OT-II T cells were labeled with 5 μM 
Cell Tracer Violet (Life Technologies). 5 × 105 cells were injected i.v. per BoyJ recipient 
mice. After 18 hours, 50 ug Ovalbumin (Sigma) mixed with Imject Alum (Pierce) was 
injected i.p. into recipient BoyJ mice. CD45.1− OT-II cells from spleen were analyzed by 
flow cyometry for CXCR5, PD1, Bcl6, Tbet and Gata3.
Peyer’s patch isolation
Peyer’s patches were cut using scissors from the small intestine and incubated for 10 mins at 
37 °C in PBS containing 1% FBS, 4mM EDTA and 15 mM HEPES (PH 7.2). Peyer’s 
patches were washed twice, with vigorous vortexing before spinning, in PBS. Soluble cell 
debris in supernatants were removed after centrifugation. Isolated Peyer’s patches were 
broken apart between two frosted glass microscope slides to generate single cell suspension 
for flow cytometry staining or ICS described above.
Bone marrow chimeras
Recipient CD45.1+ BoyJ mice were lethally irradiated with 1,100 Rad and reconstituted 
with 2×106 a mixture of nucleated bone marrow (BM) cells from either CD45.2+ WT mice 
plus CD45.1+ BoyJ mice, or CD45.2+ STAT3KO mice plus CD45.1+ BoyJ mice by i.v. 
injection. Thus, WT chimeras were used as a control to compare the repopulation of Stat3+ 
CD45.2+ BM with the repopulation by STAT3KO CD45.2+ BM. This system has been 
described previously (9). Chimeric mice were immunized with SRBC approximately 12 
weeks after reconstitution.
Antibody titer analysis
Antibody titers of SRBC-specific in serum were measured by ELISA, as previously reported 
(33). Briefly, 96 well Nunc-Immuno plates (Sigma) were coated with SRBC membrane 
protein overnight at 4 °C. Wells were blocked with 10% FCS and diluted serum was added 
and incubated at room temperature for 2 h. A peroxidase-conjugated anti-mouse IgG1 (BD), 
anti-mouse IgG or anti-mouse IgM Abs (Sigma) were used as secondary Ab.
Statistical Analysis
All data analysis was done using Prism Graphpad software. Unless otherwise stated, Student 
t test or ANOVA with Tukey post hoc analysis were used. Only significant differences (P < 
0.05) are indicated in Figures.
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Results
TFH cell development in the Peyer’s patch can occur independent of Stat3, and Stat3 
regulates the cytokine response of TFH cells
In order to analyze the role of Stat3 in TFH cell development, we obtained conditional 
knockout mice in which Stat3 is deleted from T cells via a CD4-cre transgene (CD4-cre 
Stat3fl/fl mice, termed STAT3KO mice)(32). Initially, we analyzed the TFH cell and GCB 
cell responses that occur in the intestinal Peyer’s patches (PPs), to determine if Stat3 in T 
cells was essential for normal homeostatic TFH cell responses and the related GCB 
responses in the PP (Figure 1). The percentage and overall numbers of CD4 T cells in PP 
were decreased significantly in the STAT3KO mice (Fig. 1B, C). As shown in Figure 1D, 
the loss of Stat3 mildly inhibited the proportion of TFH cells developing from the CD4 T cell 
compartment in the PP (Fig. 1D), and the absolute number of PP TFH cells in STAT3KO 
mice was about one third of the number in WT PP (Fig. 1E). However, the loss of Stat3 in T 
cells did not significantly affect the development of PP GCB cells (Fig. 1G). Loss of Stat3 in 
TFH cells did affect the rate of GCB cells in the PP switching to IgG1, as dramatically 
increased percentages of IgG1+ GCB cells were seen in the PP of STAT3KO mice (Fig. 1 I-
K). This result was confirmed by ELISPOT assays showing significantly increased numbers 
of IgG1-producing cells in the PP of STAT3KO mice (Fig. 1L). IgA-producing plasma cells 
were not altered in the STAT3KO PP, although there was a trend towards decreased levels 
of fecal IgA in STAT3KO mice (data not shown).
We next wondered what could account for the increased percentages of IgG1+ GCB cells in 
STAT3KO mice and decided to examine cytokine production by PP TFH cells. As shown in 
Figure 2A-B, PD1hi Bcl6hi T cells (TFH cells) from STAT3KO mice PP produce markedly 
higher percentages of IFNg- and IL-4-positive cells as detected by intracellular cytokine 
staining (ICS). Representative ICS cytokine flow plots are shown in Supplementary Figure 
1. As expected for loss of Stat3 activity, IL-21 was significantly lower in STAT3KO PP TFH 
cells (Fig. 2B). Non-TFH cells produced much lower levels of cytokines (Fig. 2C), and 
STAT3KO PP non-TFH cells expressed more IFNg, IL-10 and less IL-21. However IL-4 
was not increased in the STAT3KO non-TFH cells (Fig. 2C), indicating a unique regulation 
of IL-4 in TFH cells. Notably, whereas WT PP TFH cells had almost no double IFNg/IL-4-
expressing cells or double IFNg/IL-10-expressing cells, the STAT3KO PP TFH cells had far 
higher levels of these double cytokine-expressing cells (Fig. 2D, E). These results indicate 
that Stat3 regulates expression of cytokines by TFH cells, and inhibits dual expression of 
cytokines. To further confirm these results and gain insight into the mechanism for increased 
IL-4 expression, we obtained WT and STAT3KO PP TFH cells by FACS, made RNA and 
cDNA directly from the purified cells and tested gene expression by QPCR. We found as 
expected, that in contrast to non-TFH cells, TFH cells constitutively express Il4 (Figure 3A). 
We found 3-fold higher levels of Il4 and the master transcription factor for Th2 cells, Gata3, 
in the absence of Stat3 (Fig. 3 A,B). We also observed significant increases in the levels of 
Bcl6 and Prdm1 (Blimp1) in the STAT3KO PP TFH cells (Fig. 3C, D). The gene encoding 
Tbet, Tbx21, was also elevated in TFH cells and non-TFH cells in the STAT3KO PP (Suppl. 
Fig. 2A).
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Stat3 is required for acute TFH cell development in the spleen and represses IL-4 
expression by TFH cells
In order to test if our results from analyzing Stat3 function in PP TFH cells were applicable 
to other TFH cell responses, we immunized mice with Sheep Red Blood Cells (SRBC), a 
potent inducer of GCB cell responses and TFH cells. Like CD4 T cells in the PP, the total 
number of CD4 T cells was also decreased in the spleen of STAT3KO mice (data not 
shown). As shown in Figure 4, Stat3 was required for development of a normal TFH cell 
response in the spleen, particularly in the early stage of the reaction, analogous to what was 
previously reported in LCMV infection (17). Thus, at 3 days post-immunization, TFH cells 
in STAT3KO spleens were 10-fold lower than WT (Fig. 4A-C), but by day 7, the response 
of the Stat3-deficient TFH cell response increased such that it trended lower but was not 
significantly different (Fig. 4D-F). We also analyzed Bcl6 expression by intracellular 
staining and found that as in the PP TFH cells, loss of Stat3 led to significantly higher Bcl6 
expression specifically in TFH cells (Fig. 4G, H). However, in contrast to the PP, the loss of 
Stat3 strongly impacted GCB cell and GCB IgG1+ cell development in the spleen: both 
responses were impaired at the early time-point and never developed above the WT level in 
the STAT3KO (Fig. 5A-D). Consistent with a decreased GCB cell reaction, anti-SRBC IgG 
titers were several fold lower in the STAT3KO, while anti-SRBC IgM levels were not 
affected (Fig. 5E-G). We next examined cytokine production by splenic STAT3KO TFH 
cells after SRBC immunization, and compared to WT TFH cells, found increased IL-4 and 
decreased IL-21 consistent with the PP TFH cells. However in contrast to the PP TFH cells, 
IFNg was decreased in STAT3KO TFH cells (Fig. 6A). As in PP, the increase in IL-4 was 
specific to the STAT3KO TFH cells, and STAT3KO non-TFH cells showed an opposite 
pattern of IFNg expression (Fig. 6B). As in the PP TFH cells, dual cytokine-expressing cells 
were significantly increased in the spleen TFH cell population (Fig. 6 C, D).
Intrinsic effects of Stat3 on TFH cell function
To confirm and extend our results, and test if the alterations in cytokine expression were an 
intrinsic effect of Stat3-deficiency on CD4 T cells, we utilized the OTII TCR transgenic 
system, where we generated both OTII TCR+ Stat3fl/fl mice and OTII TCR+ CD4-cre 
Stat3fl/fl mice. These OVA-specific CD4 T cells were transferred to congenic recipients, 
immunized with OVA-Alum, and donor TFH cell cytokine production was assayed by flow 
cytometry (Fig. 6 E, F). In this system, Stat3-deficient T cells produced TFH cells, but at a 
significantly lower percentage than control T cells (Fig. 7A). Notably and consistent with 
our earlier results, the Stat3-deficient TFH cells produced significantly more IL-4, and also 
had an increase in double cytokine-expressing cells. The Ova-specific Stat3-deficient TFH 
cells also expressed higher levels of Gata3 and Bcl6 as well as Tbet (Suppl. Fig. 2B-D), 
consistent with the Stat3-deficient TFH cells in the PP. Thus, Stat3 plays a critical role in 
controlling IL-4 expression in TFH cells and is intrinsically required for the de novo 
generation of TFH cells in an acute antigen challenge environment.
To further test TFH cell intrinsic effects of Stat3, we utilized a mixed bone marrow (BM) 
chimera system where BM from CD45.2+ STAT3KO mice was mixed with CD45.1+ WT 
BoyJ BM and transferred into lethally irradiated WT BoyJ mice. Mice where BM from 
CD45.2+ WT (Stat3fl/fl) mice was mixed with CD45.1+ WT BoyJ BM and similarly 
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transferred into lethally irradiated CD45.1 WT BoyJ mice were used as the control for the 
STAT3KO chimeras. The mice were allowed to repopulate their lymphoid systems for at 
least 90 days, and then were immunized with SRBC. Both WT and STAT3KO donor BM 
CD4 T cells re-populated the spleen normally in the absence of Stat3 (Fig. 7B). However, in 
contrast to our results with whole conditional mutant animals, Stat3-deficient CD4 T cells in 
chimeric mice formed TFH cells at a markedly lower rate than control cells in the PP, 
whereas splenic TFH cells were less affected (Fig. 7C). These results suggest that in a 
competitive environment with wild-type TFH cells, Stat3-deficient TFH cells can develop to 
a significant degree, but in a chronic, ongoing response as in the PP, do not persist as well as 
wild-type TFH cells. The proportion of GCB cells was not affected by the presence of Stat3-
deficient TFH cells, and likely the wild-type TFH cells compensated for any defect of the 
Stat3-deficient TFH cells (Fig. 7D). GCB cells showed a non-significant trend towards 
increased IgG1, which would fit with a model where increased IL-4 made by Stat3-deficient 
TFH cells was diluted out by wild-type TFH cells (Fig. 7E). In the chimeric PP, we examined 
cytokine production and consistent with our results in non-chimeric mice, we observed 
increased IFNg and IL-4, and decreased IL-21 in Stat3-deficient TFH cells (Suppl. Fig. 2E-
G). Thus, the altered cytokine expression in Stat3-deficient TFH cells is cell intrinsic. In the 
chimeric spleen, we further examined the expression of Bcl6 and Gata3, and found these 
two key transcription factors were significantly increased in Stat3-deficient TFH cells in both 
PP and SP (Fig. 7F, G). Thus, deregulated Bcl6 and Gata3 expression in Stat3-deficient TFH 
cells is an intrinsic effect of loss of Stat3 in the TFH cells, and is not a function of an 
abnormal immune environment present in STAT3KO mice.
To better understand how Stat3 was required for TFH cell development, we wondered if 
Stat3-deficient CD4 T cells proliferated poorly or underwent greater apoptosis, thus leading 
to non-competitive TFH cell responses. To test this, we used T cells from WT and 
STAT3KO OTII TCR mice, where the cells were labeled with a cell tracking dye prior to 
transfer. Six days after OVA-Alum immunization, we found that the Stat3-deficient T cells 
demonstrated slightly greater proliferation than the control cells (Suppl. Fig. 3A, B). We 
additionally analyzed the rate at which Stat3-deficient TFH cells underwent apoptosis, using 
two different methods. We tested the ex vivo level of TFH cells initiating apoptosis by 
staining TFH cells for AnnexinV, both in spleen after SRBC immunization and in PP. We 
also tested whether the Stat3-deficient TFH cells might undergo higher apoptosis if they 
were stimulated through the TCR. TFH cells were isolated by FACS from spleens of SRBC-
immunized mice, stimulated overnight with anti-CD3 Ab, and then measured for levels of 
active caspase 3. Contrary to expectations from the lack of in vivo competitiveness in 
chimera mice, the Stat3-deficient TFH cells had fewer or equal levels of apoptotic cells 
(Suppl. Fig. 3C-E).
Control of Bcl6 repressive activity by Stat3
To better dissect why Stat3-deficient TFH cells expressed more IL-4, we used an Ova 
antigen plus APC in vitro culture system where OTII TCR control and OTII TCR Stat3-
deficient CD4 T cells were activated under TH2 conditions, and IFNg and IL-4 expression 
were monitored by ICS after 3 days (Fig. 8A). Consistent with what we observed for Stat3-
deficient TFH cells, Stat3-deficient CD4 T cells cultured under TH2 conditions produced 
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about twice as much IL4, and like the Stat3-deficient TFH cells, double cytokine-expressing 
cells were also increased (Fig. 8B). Similar increases in double cytokine-expressing cells 
were also observed in Stat3-deficient CD4 T cells cultured under TFH conditions, but the 
level of IL-4 single expressing cells was lower in the Stat3-deficient cells (Suppl. Fig. 4). 
Notably, the increased IL-4 production by STAT3KO Th2 cells was transient, as STAT3KO 
T cells cultured longer under Th2 conditions produced significantly less IL-4 than the 
control Th2 cells (Fig. 8C). Bcl6 is known to suppress IL-4 expression in CD4 T cells in part 
by suppressing Gata3 transcriptional activity (34, 35), so we wondered why the increased 
Bcl6 expression in Stat3-deficient TFH cells failed to control IL-4. We therefore tested 
whether forced expression of Bcl6 by retrovirus (RV) could suppress IL-4 in Stat3-deficient 
CD4 T cells cultured under TH2 conditions. For this experiment, CD4 T cells from control 
and STAT3KO mice were activated under Th2 conditions using anti-CD3 and anti-CD28 
Abs plus APC. Under these conditions, about 50% of control T cells expressed IL-4 and a 
higher level, about 70% of Stat3-deficient T cells expressed IL-4 (Fig. 8D). Whereas Bcl6 
RV was able to suppress over 60% of the IL-4 in control T cells, it suppressed less than 30% 
of the IL-4 in Stat3-deficient T cells (Fig. 8D, G). This strong loss of Bcl6 repressive 
activity was unique to IL-4, as Bcl6 repressed IL-10 slightly better in Stat3-deficient T cells 
(Fig. 8E, G) and Bcl6 showed only a slight defect in repressing IL-13 (Fig. 8F, G). These 
data show that Bcl6 is defective in repressing IL-4 expression in the absence of Stat3, and 
this can explain the abnormal expression of IL-4 by Stat3-deficient TFH cells.
Discussion
TFH cells control germinal center reaction and the production of high affinity antibodies to 
antigen, and the pathways for how TFH cells develop and regulate B cell responses are a 
major part of the adaptive immune response. When we initiated this study, we were 
interested in elucidating how critical Stat3 was for TFH cell differentiation and if other 
pathways besides Stat3 could induce Bcl6 expression in TFH cells. Recent studies have 
revealed that TFH cells can develop at a low level in the absence of Stat3 (18), and that Stat4 
and Stat1 can participate in inducing Bcl6 during TFH cell differentiation (14, 16, 17). The 
work of Ray et al (18) established that Stat3 is critical factor for not only activating Bcl6 in 
TFH cells but also for repressing a Type I IFN pathway that induces a TH1-like effector 
program in TFH cells. However, since this study was done solely in the context of acute 
LCMV infection where a great deal of Type I IFN is produced, whether this pathway 
represented the dominant Stat3-mediated control pathway in TFH cells, or only was 
operative in the case of virus infection, was unclear. Thus, we analyzed T cell specific Stat3 
conditional KO mice (CD4-cre Stat3fl/fl; STAT3KO) for other types of TFH cell responses. 
In the ongoing chronic TFH cell/GCB cell response of the PP, we found that loss of Stat3 did 
not affect the proportion of the TFH cells within the PP, nor did loss of Stat3 in TFH cells 
affect the level of PP GCB cells. Furthermore, there was a shift towards the expression of 
both TH1 (IFNg) and TH2 (IL-4) cytokines in Stat3-deficient PP TFH cells. We observed that 
Bcl6 expression was notably higher in Stat3-deficient PP TFH cells. These data indicate that 
Stat3 function in TFH cells can vary depending on the type of immune response, and that 
Stat3 appears to insulate TFH cells from differentiating into different effector pathways 
depending on the cellular micro-environment. Most dramatic, though was our finding that 
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PP TFH cells and GCB cell responses were present at normal levels in the STAT3KO mice, 
with increased Bcl6 expression by TFH cells. The function of Stat3 in regulating Bcl6 
expression in TFH cells is therefore heavily influenced by the local immune environment. In 
a virus infection with high levels of Type I IFN, Stat3 is required for up-regulating Bcl6 in 
TFH cells, but in the immune response against commensal organisms in the PP, Stat3 
actually restrains the up-regulation of Bcl6 in TFH cells. In the anti-virus response, Type I 
IFN suppresses Bcl6 expression, and it was proposed that Type I IFN leads to IL-2 gene 
transcription and downstream Stat5 activation, where Stat5 then directly binds to and 
represses Bcl6 (18). In contrast, for the gut-PP immune environment and for antigens where 
Type I IFN is not produced, such as Ova-Alum, Stat5 is likely not activated in TFH cells. We 
propose that lack of Stat3 in this inactive Stat5 TFH context allows other Stats, such as Stat1 
and Stat4, to bind to the Bcl6 promoter and more strongly activate transcription than when 
Stat5 is active.
A related question is why IL4 and IFNg are up-regulated in Stat3-deficient TFH cells. We 
observed increased IL-4 in all four types of TFH cell responses we tested (PP, SRBC 
immunization, OVA-Alum immunization and in vitro activation under TH2 conditions), and 
thus it seems to be a general effect in our hands. IFNg was increased in Stat3-deficient PP 
TFH cells and the in vitro cultures. Thus, the immune environment is key for the exact type 
of cytokine response that Stat3 regulates in TFH cells. Our data with Bcl6 RV show that 
Bcl6 is unable to suppress IL-4 in the absence of Stat3, but the mechanism for this effect is 
not clear. One possibility is the increased Gata3 we observe in CD4 T cells in the absence of 
Stat3. Gata3 may put the IL-4 gene chromatin in a hyper-activated state that is resistant to 
repression by Bcl6. A related possibility is that there is differential regulation of IL-4 by Stat 
factors in the absence of Stat3. This model is analogous to the model for regulation of Bcl6 
transcription in the absence of Stat3 described above. Thus, this model would propose that 
IL-4 gene expression is controlled by loss of Stat3 differently in the virus infection system 
versus immune responses where Type I IFN is not produced, such as the responses we 
analyzed in this study. In the absence of Type I IFN and activation of Stat1, other Stat 
factors may bind to IL-4 or Gata3 regulatory regions and induce high-level expression of 
these genes. Yet another possibility is that Stat3 regulates the transcription of a co-factor 
required for repression of IL-4 by Bcl6. The exact mechanism for how Bcl6 represses IL-4 
expression in CD4 T cells is not known, though the current model is that Bcl6 represses 
Gata3 transcriptional activity, and thus indirectly suppresses IL-4 gene expression (35, 36).
Our data showing increased IL-4 by T cells in the absence of Stat3 contrasts with published 
work showing that Stat3 is required for proper full TH2 cell differentiation (32). A possible 
explanation for this discrepancy is that TFH cells regulate IL-4 gene expression by different 
regulatory elements than the regulatory elements that TH2 cells use for IL-4 expression (37, 
38), and overall it is clear that TFH cells are a separate lineage from TH2 cells. At the same 
time, we observed increased IL-4 expression by Stat3-deficient T cells cultured under TH2 
conditions (Fig. 8). Critically, in the in vitro TH2 cultures, we analyzed IL-4 and other 
cytokines in these Stat3-deficient TH2 cells at an early time point: 3 days after initial 
activation. When we examined Stat3-deficient TH2 cells cultured for longer periods and 
after re-stimulation (Fig. 8C), the increased IL-4 expression was lost. Indeed, data in the 
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previous report also showed that IL-4 production within the first 24-48 hours was not 
deficient in the absence of Stat3 (39). Thus, we can reconcile these findings then by 
proposing that Stat3 indeed suppresses expression of IL-4 shortly after activation, but that 
Stat3 is actually important for long-term TH2 cell stability and/or survival.
Curiously, we found that Stat3-deficient TFH cells survive about the same or slightly better 
than wild-type TFH cells (Suppl. Fig. 3C-E), which contradicts the standard view that Stat3 
is a pro-tumor and pro-survival transcription factor (15, 20, 40). One explanation is that the 
increased survival of Stat3-deficient TFH cells is due to increased Bcl6 expression, since we 
have previously shown a survival effect of Bcl6 in TFH cells (33). Whether this effect is 
unique to TFH cells and holds up tp further scrutiny will require investigation.
In summary, we have revealed a much more complete picture of how Stat3 regulates TFH 
cell development and function. Stat3 function in TFH cells appears to be strongly dependent 
on the immune environment, and Stat3 plays very different regulatory roles in TFH cells that 
develop during virus infection than in TFH cells that develop in response to commensal 
organisms in the gut, as well to model antigens that do not provoke a strong type I IFN 
response. In the larger picture, our data indicate a critical role for Stat3 antagonizing the 
activity of other Stat factors that are activated in CD4 T cells during the immune responses. 
Notably, Stat3 can act in TFH cells to either repress Bcl6 or to activate Bcl6, depending on 
the activation of other Stat factors.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Effect of the loss of Stat3 in T cell on TFH cell numbers, germinal center B (GCB) cell 
numbers, and IgG1 class switching in the Peyer’s Patch (PP)
A) TFH cells are gated on Foxp3−CXCR5hiPD1hi cells within the CD4+ population, 
examples from PP of Stat3fl/fl (WT) and CD4-cre Stat3fl/fl (STAT3KO) mice are shown. 
Percentages within the PP (B) and absolute numbers (C) of total PP CD4 cells. D) Average 
PP TFH cell percentages within the CD4 T cell population in WT and STAT3KO mice. E) 
Absolute numbers of PP TFH cells in WT and STAT3KO mice. F) GCB cells are gated on 
Fas+GL7+ cells within the B220+ population, examples from PP of WT and STAT3KO 
mice are shown. Average PP GCB cell populations by percentage (G) and absolute number 
(H). (I) Histogram showing IgG1+ GCB cells from WT and STAT3KO, gated on the GCB 
population. Average IgG1+ GCB cell populations in terms of percentage (J) and absolute 
number (K). L) IgG1 secreting cells in 3×105 WT and STAT3KO total PP cells, assayed by 
ELISPOT. (n=3, mean ± SEM). Each symbol represents one mouse (n=12, mean ± SEM). 
Data are combined from four independent experiments, except for ELISPOT, which was 
repeated once. *P <0.05, **P <0.01, ***P <0.001 by t-test.
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Figure 2. Deregulated cytokine production in Stat3-deficient TFH cells in the PP
(A) PD1hi and PD1int CD4+ cell gates and increased Bcl6 mean fluorescent intensity (MFI) 
on the PD1hi population. Fixation for ICS degrades CXCR5 staining and thus for ICS, TFH 
cells are defined as CD4+PD1hi. Average percentage and absolute number of cytokine-
producing (IFNg+ (IFNγ+), IL-4+, IL-10+ and IL-21+) in CD4+PD1hi TFH (B) and 
CD4+PD1neg (C) cells from WT and STAT3KO PP measured by intracellular cytokine 
staining (ICS) (n=12, mean ± SEM). Average percentage and absolute number of double 
cytokine-producing (D) IFNg+IL-4+ and (E) IFNg+IL-10+ populations in PD1hiCD4+ T 
cells. Each symbol represents one mouse (n=12, mean ± SEM). Data are combined from 
four independent experiments. *P <0.05, **P <0.01, ***P <0.001 by ANOVA (B-C) or t-
test (D-E).
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Figure 3. Altered gene expression in Stat3-deficient TFH cells in the PP
Relative mRNA expression was determined by Quantitative RT-PCR (Q-RT-PCR). A) Il4 
gene expression from freshly-isolated PP TFH and non-TFH cells (CXCR5-PD1-) from WT 
and STAT3KO mice (n=4, mean ± SEM). *P <0.05 (ANOVA). B-D) Bcl6, Prdm1 and 
Gata3 gene expression in freshly-isolated PP TFH cells. TFH cells were gated for flow 
cytometry as in Figure 1. Each symbol represents one mouse (n=4, mean ± SEM). *P <0.05, 
**P <0.01, ***P <0.001 (t-test).
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Figure 4. Delayed TFH cell responses in the spleen of Stat3-deficient conditional knockout mice 
after immunization
A) TFH cells are gated on CD4+Foxp3− CXCR5hiPD1hi cells within the splenocyte 
population. Average TFH cell percentages (B) and absolute numbers (C) in WT and 
STAT3KO mice (n=4, mean ± SEM), 3 days post-immunization (dpi) with Sheep Red 
Blood Cells (SRBC). D) Day 7 TFH cells are gated as in (A). Average TFH cell percentages 
(E) and absolute numbers (F) in WT and STAT3KO mice (n=4, mean ± SEM), 7 dpi with 
SRBC. G) Bcl6 MFI of TFH cells at 7 dpi (n=3, mean ± SEM). H) Bcl6 MFI of non-TFH 
cells at 7 dpi (n=3, mean ± SEM). **P <0.01, ***P <0.001 (t-test). Each symbol in graphs 
represents one mouse. Data are representative of two independent experiments with similar 
results.
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Figure 5. Weak GCB cell responses and antibody responses following SRBC immunization when 
Stat3 is absent in T cells
Mice were immunized with SRBC and spleen analyzed 3 or 7 dpi. (A, C) GCB cells and (B, 
D) IgG1+ GCB cells were gated as in Figure 1. Average GCB cell populations in terms of 
percentage of B220+ cells and absolute number at 3 dpi (A, B) and 7 dpi (C, D). Each 
symbol represents one mouse (n=3-4, mean ± SEM). *P <0.05, **P <0.01 (t-test). Data are 
representative of two independent experiments with similar results. (E-G) Anti-SRBC Ab 
responses measured by ELISA at 7 dpi. (E) anti-SRBC IgM, (F) anti-SRBC IgG and (G) 
anti-SRBC IgG1 titers (n=4, mean ± SEM). *P <0.05, **P <0.01, ***P <0.001
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Figure 6. Stat3 controls IL-4 expression in TFH cells under multiple conditions
Cytokines expressed by TFH cells were measured by ICS and TFH cells were gated as in 
Figure 2. A) Average percentage and absolute number of cytokine-producing (IFNg+ (IFNγ
+), IL-4+, IL-10+ and IL-21+) TFH cells in the spleens of WT and STAT3KO mice 7 dpi 
with SRBC (n=7-9, mean ± SEM). B) Average percentage and absolute number of cytokine-
producing (IFNg+ (IFNγ+), IL-4+, IL-10+ and IL-21+) non-TFH cells in the spleens of WT 
and STAT3KO mice 7 dpi with SRBC (n=7-9, mean ± SEM). Average percentage and 
absolute number of double cytokine-producing IL-10+IL-4+ (C) and IFNg+IL-4+ (D) cells 
within the populations assayed in (A). Each symbol represents one mouse (n=7-9, mean ± 
SEM). (E-F) WT and STAT3KO OTII TCR transgenic CD45.2+ CD4+ T cells were 
transferred to CD45.1+ BoyJ mice, and the recipient BoyJ mice were immunized with OVA-
Alum. TFH cells were analyzed for cytokine expression at 6 dpi. Graphs show average 
percent of cells expressing single cytokines (IFNg, IL-4 and IL-10) and double cytokine-
producing cells in the CD45.1-PD1hiCD4+ T cell population (n=3, mean ± SEM). *P <0.0, 
***P <0.001.
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Figure 7. Intrinsic defect of Stat3-deficient TFH cell development
(A) WT OTII TCR transgenic and STAT3KO OTII TCR transgenic CD45.2+ CD4+ T cells 
were transferred to separate cohorts of CD45.1+ BoyJ mice, and recipient BoyJ mice were 
immunized with OVA-Alum. Graph shows average percent TFH cells within the transferred 
T cell population, analyzed at 6 dpi. (B-G) CD45.1+ BoyJ mice were lethally irradiated and 
divided into two groups. The WT group was given a mixture of bone marrow (BM) from 
BoyJ mice and CD45.2+ Stat3fl/fl (WT) mice. The STAT3KO group was given a mixture of 
bone marrow (BM) from BoyJ mice and CD45.2+ CD4-cre Stat3fl/fl (STAT3KO) mice. 
After 90 days, the mice were immunized with SRBC. At 7 dpi, the mice were analyzed for 
percentages of transferred BM-derived CD45.1− CD4 T cells in spleen (B), and percent of 
TFH cells (C) and GCB (D) in spleen (SP) and PP. Graphs show average percentage of 
CD45.1− (CD45.2+) cells in the WT and STAT3KO groups. TFH cells were analyzed by 
flow cytometry as in Figures 1 and 4. E) IgG1+ GCB cell percentages in spleen and PP 
(n=4, mean ± SEM). ***P <0.05 (t-test). D-E) MFI of CD45.1− TFH cells in spleen (SP) and 
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PP for Bcl6 (F) and Gata3 (G). (n=4, mean ± SEM). *P <0.05, **P <0.01, ***P <0.001 (t-
test). Data are representative of two independent experiments with similar results.
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Figure 8. Defective Suppression of IL-4 by Bcl6 in Stat3-deficient T cells
(A-B) WT and STAT3KO OTII TCR transgenic CD4+ T cells were cultured under Th2 
conditions with APC and OVA peptide in vitro for 3 days. Cells were then stimulated with 
PMA plus ionomycin and analyzed for IFNg and IL-4 ICS by flow cytometry. A) Sample 
staining of WT versus STAT3KO T cells after one round of stimulation and Th2 culture 
(n=3, mean ± SEM). B) Average percentages of IFNg+IL-4−, IFNg+IL-4+ and IFNg−IL-4+ 
cell CD4+ T cells after one round of stimulation and culture under Th2 conditions for 3 days 
(n=3, mean ± SEM). C) Average percentages of IFNg+IL-4−, IFNg+IL-4+ and IFNg-IL-4+ 
cell CD4+ T cells after an additional stimulation and 5 days of Th2 culture (“2nd Th2”, n=3, 
mean ± SEM). (D-G) WT and STAT3KO CD4+ T cells under Th2 condition and infected 
with Bcl6-expressing and control retroviruses (RVs). Average percentages of T cells 
expressing (D) IL-4, (E) IL-10, (F) IL-13 assayed by ICS, after PMA plus ionomycin 
stimulation of WT + control RV, WT + Bcl6 RV, STAT3KO + control RV and STAT3KO 
+ Bcl6 RV CD4+ T cells (n=3, mean ± SEM). G) Analysis of data in (D-F) showing average 
percent suppression by Bcl6 RV in WT and STAT3KO CD4 T cells. Percent suppression = 
((% cytokine+ cells with control RV minus % cytokine+ cells with Bcl6 RV) divided by % 
cytokine+ cells with control RV) × 100. Data are representative of two independent 
experiments with similar results. *P <0.05, **P <0.01, ***P <0.001 (ANOVA).
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